Market Announcement
August 24, 2023

Advanced Health Intelligence Ltd
Company Presentation -
Smartphone Biometric Health Assessment

South Perth, Australia August 24, 2023 - **Advanced Health Intelligence Ltd (ASX/NASDAQ: AHI) ("AHI" or the "Company")** is pleased to release its latest Company Presentation.

This presentation highlights the advancements made in AHI's Smartphone Biometric Health Assessment capabilities. Designed specifically for deployment from a smartphone device, this innovative application leverages AHI's proprietary process of capturing biometric data, providing users with comprehensive health insights.

AHI has tailored this presentation for its shareholders to assist in understanding the company's technology, business case and targeted market segments. AHI wishes to ensure our shareholders remain informed about the Company's pioneering developments and future prospects.

The Chairman and CEO of Advanced Health Intelligence Ltd have approved this announcement.

For more information, contact:

Scott Montgomery
Chief Executive Officer
Advanced Health Intelligence Ltd
E: admin@ahi.tech

Vlado Bosanac
Founder/Head of Strategy
Advanced Health Intelligence Ltd
E: admin@ahi.tech

About Advanced Health Intelligence Ltd

Advanced Health Intelligence Ltd (AHI) is committed to becoming a global leader in digital health, harnessing its proprietary technology and innovative processes to redefine health screening. Leveraging the ubiquity and convenience of smartphones, AHI aims to deliver a comprehensive suite of assessment tools to healthcare providers, caregivers, insurers, and governments around the world.

Our mission is to improve healthcare outcomes, enhance health literacy, and support the early detection and management of various health conditions.

Since our inception in 2014, AHI has been at the forefront of Health-tech innovation, starting with the world's first on-device body dimensioning capability. Our patented technology has evolved into a robust suite of solutions symbolising digitised healthcare's future.

Our key offerings include:

- Body dimension and composition assessments enable the identification of obesity-related comorbidities such as diabetes.
- Blood biomarker prediction includes HbA1C, HDL, LDL, and 10-year mortality risk.
- Transdermal Optical Imaging, providing vital signs and cardiovascular disease risk estimates.
- On-device dermatological skin identification recognises 588 skin conditions across 133 categories, including Melanoma.
- Assisting partners in delivering personalised therapeutic and non-therapeutic health coaching to improve daily habits and build health literacy.

At the heart of AHI is our world-class team comprising machine learning and AI experts, computer vision specialists, and medically trained data scientists. Their collective expertise ensures AHI remains at the cutting edge of health-tech innovation, tailoring our technology to meet the evolving needs of our consumers.

AHI's vision extends beyond individual health assessments. We aspire to create a transformative impact at scale, driving forward a new era in digital healthcare. Our biometrically derived triage solution, accessible via a smartphone, enables our partners to identify and manage health risks at a population scale.

In the pursuit of proactive health management, AHI stands ready to guide healthcare providers, caregivers, insurers, and governments in triaging individuals into the most suitable care pathways. Through technology, AHI is contributing to a more efficient, effective, and inclusive global healthcare system.

For more information about AHI and its research initiatives, please visit: www.ahi.tech

Smartphone Biometric Health Assessment

AUGUST 2023

Confidential – Do not duplicate or distribute without the written permission of Advanced Health Intelligence Ltd

This presentation ("Presentation") has been prepared by **Advanced Health Intelligence Ltd** ("Advanced Health Intelligence" or "Company").

You must read and accept the conditions in this notice before considering the information set out in or referred to in this Presentation. If you do not agree, accept or understand the terms on which this Presentation is supplied, or if you are subject to the laws of any jurisdiction in which it would be unlawful to receive this Presentation or which requires compliance with obligations that have not been complied with in respect of it, you must immediately return or destroy this Presentation and any other confidential information supplied to you by Advanced Health Intelligence. By accepting this document, you acknowledge and agree to the conditions in this notice and agree that you irrevocably release Advanced Health Intelligence from any claims you may have (presently or in the future) in connection with the provision or content of this Presentation.

NO OFFER

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction (and will not be lodged with the ASIC).

This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire shares of Advanced Health Intelligence and does not and will not form any part of any contract for the acquisition of shares of Advanced Health Intelligence.

SUMMARY INFORMATION

This Presentation contains summary information about Advanced Health Intelligence, its subsidiaries and their activities which is current as at the date of this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Advanced Health Intelligence or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act. While Advanced Health Intelligence has taken every effort to ensure the accuracy of the material in the presentation, neither the Company nor its advisers have verified the accuracy or completeness of the information, or any statements and opinion contained in this Presentation.

NOT INVESTMENT ADVICE

Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of Advanced Health Intelligence and the impact that different future outcomes may have on Advanced Health Intelligence.

This Presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. Advanced Health Intelligence is not licensed to provide financial product advice in respect of Advanced Health Intelligence shares.

Cooling off rights do not apply to the acquisition of Advanced Health Intelligence shares.

INVESTMENT RISK

An investment in Advanced Health Intelligence shares is subject to known and unknown risks, some of which are beyond the control of Advanced Health Intelligence. Advanced Health Intelligence does not guarantee any particular rate of return or the performance of Advanced Health Intelligence nor does it guarantee any particular tax treatment. An investment in Advanced Health Intelligence should be considered as Highly Speculative and High Risk due to the start up nature of the Company and its proposed business.

FINANCIAL DATA

All dollar values in this Presentation are in Australian dollars (A$ or AUD) unless otherwise stated.

FORWARD-LOOKING STATEMENTS

This Presentation may contain forward looking statements. The words 'anticipate', 'believe', 'expect', 'project', 'forecast', 'estimate', 'likely', 'intend', 'should', 'could', 'may', 'target', 'plan' and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements are subject to risk factors associated with the Company's business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements. You should not place undue reliance on forward- looking statements and neither Advanced Health Intelligence nor any of its directors, employees, advisers or agents assume any obligation to update such information.

DISCLAIMER

None of Advanced Health Intelligence's respective advisers or any of their respective affiliates, related bodies corporate, directors, officers, partners, employees and agents, have authorized, permitted or caused the issue, submission, dispatch or provision of this Presentation and, except to the extent referred to in this Presentation, none of them makes or purports to make any statement in this Presentation and there is no statement in this Presentation which is based on any statement by any of them.

To the maximum extent permitted by law, Advanced Health Intelligence and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents exclude and disclaim all liability, including without limitation for negligence or for any expenses, losses, damages or costs incurred by you as a result of your participation in an investment in Advanced Health Intelligence and the information in this Presentation being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise.

To the maximum extent permitted by law, Advanced Health Intelligence and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this Presentation.

Statements made in this Presentation are made only as the date of this Presentation. The information in this Presentation remains subject to change without notice.

Unique and growing

Our vision is ubiquitous health monitoring

AHI is committed to becoming a global leader in digital health, leveraging proprietary technology and innovative processes to redefine the landscape of health screening. With the ubiquity and convenience of smartphones, AHI's vision is to deliver a comprehensive and accessible suite of assessment tools to a broad spectrum of users, including healthcare providers, caregivers, insurers, and governments around the world.

Our mission is to improve healthcare outcomes, enhance health literacy, and support the early detection and management of various health conditions. AHI's vision extends beyond individual health assessments; we aspire to create a transformative impact at scale, driving forward a new era in digital healthcare that reaches populations globally.

Since our inception in 2014, AHI has been at the forefront of Health-tech innovation, starting with the world's first on-device body dimensioning capability. Our patented technology has evolved into a robust suite of solutions symbolizing the future of digitized healthcare. Key offerings include:

- Body Dimension and Composition Assessments: These enable the identification of obesity-related comorbidities such as diabetes, providing critical insights into individual health.
- Blood Biomarker Prediction: Includes vital markers like HbA1C, HDL, LDL, and a 10-year mortality risk, offering a comprehensive view of a person's health status.
- Transdermal Optical Imaging: A cutting-edge technology providing vital signs and cardiovascular disease risk estimates, enhancing preventive care.
- On-Device Dermatological Skin Identification: Recognizes 588 skin conditions across 133 categories, including Melanoma, offering early detection and intervention.
- Assisting partners in delivering therapeutic and non-therapeutic assessments to improve daily habits, build health literacy, and foster long-term well-being.

At the heart of AHI is our world-class team comprising machine learning and AI experts, computer vision specialists, and medically trained data scientists. Their collective expertise ensures AHI remains at the cutting edge of health-tech innovation, tailoring our technology to meet the evolving needs of our consumers.

AHI's biometrically derived triage solution, accessible via a smartphone, enables our partners to identify and manage health risks at a population scale. This approach aligns with our goal of proactive health management, guiding healthcare providers, caregivers, insurers, and governments in triaging individuals into the most suitable care pathways.

Through technology, AHI is contributing to a more efficient, effective, and inclusive global healthcare system. We stand ready to lead the way in digital healthcare, embracing the challenges and opportunities of the future, and working collaboratively with partners around the world to enhance the quality of life for all.

Scott Montgomery

Chief Executive Officer

Vlado Bosanac

Founder / Head of Strategy

Corporate overview

Advanced Health Intelligence (ASX – NASDAQ:AHI) is a global digital health solution.

- AHI sells its dHaaS (digital health-as-a-service) technology **to healthcare, insurance and government** customer segments around the world in a business-to-business model (**B-to-B**).
- **AHI completed two acquisitions in 2022, expanding** its capabilities to offer mass population health monitoring using only a user's smartphone.
- AHI holds **patents in Australia, USA, Japan, Korea, Singapore, New Zealand, China and Canada** and expects to add to the patent portfolio.
- **AHI screens for health risk stratification using only a smartphone by capturing biometric data,** including vital signs, body composition, dimension, and indicative blood markers. In addition, AHI offers DermaScan which covers 588 skin conditions across 133 categories.
- AHI enables its partners to estimate **41 biometrics across 5 health categories** in order to triage their users into directionalized care

Advanced Health Intelligence (ASX/NASDAQ:AHI) is a global digital health solution

Issuer	Advanced Health Intelligence Ltd
Exchange	Australian Securities Exchange (ASX) & Nasdaq Capital Market (NASDAQ)
Shares on issue As at 1 Aug 2023	217,703,969 including ADR cover
NASDAQ ADR - ADR Ratio 28:1	2,246,800
Employee headcount	32 across Australia, Singapore, USA, Canada, South Africa, Netherlands.
Current partners addressable audience	> 400 million addressable users across AHI's current partners
Intellectual property	24 patents, across Australia, USA, Japan, Korea, Singapore, New Zealand, China And Canada

The world's largest companies are in digital health

Advanced Health Intelligence's capabilities augment all of these solutions for a truly unique in market offering.

> *The magic is what happens when you bring them all together, when you use technologies to surround the patients in their reality on a regular basis. The way to achieve this 'omnipresence' is to use automation to move beyond the usual supply and demand constraints in healthcare"*
>
> **Roy Schoenberg, CO-CEO AMWELL on his $320m acquisitions of SilverCloud and Conversa[1]**

Oracle Cerner
ACQUISITION ($943/USER)
US $20B
completed Jun 2022

Microsoft Nuance
ACQUISITION
US $19.7B
completed Mar 2022

amazon one medical
ACQUISITION ($5400/USER)
US $2.8B
completed Jul 2022

IBM Watson
FP Francisco Partners
ACQUISITION (EST. $1B)
UNDISCLOSED
completed Jun 2022

Google fitbit
ACQUISITION ($72/USER)
US $2.1B
completed Jan 2021

Walmart MeMD
ACQUISITION
UNDISCLOSED
Launched May 2022

Virgin pulse
Welltok
ACQUISITION
UNDISCLOSED
completed Nov 2021

Teladoc HEALTH
Livongo
ACQUISITION
US $18.5B
completed Oct 2020

ByteDance
amcare
ACQUISITION
US $1.5B
announced Aug 2022

The realities of the rising costs in healthcare

Global healthcare expenditure to reach 10% of GDP by 2040

The rising costs of healthcare have become a global challenge and a major reality for both developed and developing countries. According to the World Health Organization (WHO), the global healthcare expenditure is projected to reach 10% of the Gross Domestic Product (GDP) by the year 2040. [4]

By streamlining health assessment and triage into a smartphone experience, AHI offers pathways into improving population health literacy and empowering individuals to take better control of their health.







Sources

1. How many smartphones are in the world?, https://bankmycell.com/
2. Noncommunicable diseases, https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases/
3. Facts about Hypertension in the United States, https://cdc.gov
4. Global spending on health: Weathering the storm https://www.who.int/publications/i/item/9789240017788

Global, private and secure.

We collaborate with our partners to establish a shared responsibility model, to ensure our digital health solutions comply with applicable regulations in those territories including HIPAA, GDPR and more. This model ensures that sensitive health information is effective protected at all touch points. Furthermore, Data Processing Agreements outlining the requirements and obligations we undertake are entered into with partners to ensure global privacy standards are met and maintained. Our technology meets OWASP standards and is consistently reviewed by independent security experts.



* HIPAA compliance applies to FaceScan and BodyScan data processing.

- No images or videos leave the device.
- Only encrypted data-signals are sent to the cloud for processing and analysis.
- Users choose who to share results with and when.

Realising digital transformation in healthcare

Biometric health assessment for global populations

Our aim is to revolutionize healthcare with our proprietary technology. This scalable technology allows the convenient and cost-effective distribution of health assessments to derive real-time risk stratification and automate digital triage at population-scale with improved accuracy.

Our comprehensive suite of digital health solutions creates a cohesive ecosystem that supports healthcare success, addressing the Triple Aim.



Population health assessments and engagement

Provide scalable access and automation through smartphones to easily assess health vital signs without need for more devices or health professionals.

Very low cost per person

Entire population

Targeted digital interventions

Personalized eHealth programs for targeted outcomes (i.e. the opposite of one-size-fits-all public health).

Very low cost per person

People identified as high risk of selected illness

Telehealth or physician consultation for condition management

Where clinically appropriate, refer into partner-selected telehealth and physician clinics.

Varies by provider

Peoplee diagnosed with selected illnesses

SUB-CLINICAL

Continuum of care

CLINCAL

Our solutions

Proactive risk management in the palm of your hand

- **All on the smartphone in approx. 10 minutes** – no additional wearables or hardware needed.
- **Remote and contactless** biometric-derived health assessment for risk estimates associated with blood pressure, heart rate, HbA1c, cholesterol, (LDL and HDL levels), triglycerides and many more.
- **Wide range of predicted health risks** including obesity, heart attack risk, stroke risk, 10-year Framingham cardiovascular disease risk, diabetes and more.
- **Seamless triage capability** - lower risk individuals can be referred into subclinical care options while moderate to higher risk can be referred into telehealth or higher care options.

Biometric health assessment

4-scans in 10-minutes for your biometric health report

01. Cardiovascular and mental health

FaceScan uses facial blood flow analysis to deliver health vital estimates including blood pressure, heart rate, heart rate variability and breathing rate. This is promptly followed by the GAD7 and PHQ9, the clinical standard for anxiety and depression risk detection.

02. Health at rest

Health at rest focusses on the cardiovascular system and predicts resting heart rate risk. FingerScan employs Photoplethysmography (PPG) technology to detects volumetric changes in blood in peripheral circulation while at rest.

03. Body dimension and composition

BodyScan is built with proprietary computer vision and machine learning processing modules, which use over 1,000's data points to generate and guide the scaled contour. This returns estimates on body dimension and composition, such as body fat %, waist hip ratio, and waist height ratio, comparable to gold standard methods.

04. Post exertion recovery

A 3-minute step test promptly followed by a FingerScan PPG to review cardiovascular fitness. This evenly paced stepping exercise reviews the associated risks with heart rate recovery and heart disease.



What's included in the report?

Estimations include:

- Cardiorespiratory fitness
- 10-year cardiovascular disease risk
- Framingham 10-year hard cardiovascular disease risk
- Resting heart rate
- Systolic blood pressure
- Diastolic blood pressure
- Blood sugar
- Body fat percentage
- Waist circumference
- Hip circumference
- Waist-to-hip ratio
- Waist-to-height ratio
- Body mass index
- General anxiety
- Depression
- Arterial stiffness
- Visceral adiposity index
- Lipid accumulation product
- Blood lipids
- LDL Cholesterol
- HDL Cholesterol
- Triglycerides
- C-reactive protein inflammation

Biometric health assessment

Bloodless. Biometric. Ubiquitous.

- 61 outputs
- 41 biometrics
- 5 health categories

Self administered biometric health assessment from a user's own smartphone, no supporting equipment or health professional required.

Helping scale GPs' health-monitoring for larger populations.



Biometric health assessment

Triage into your desired care pathways

Promote of early-risk detection and encourage sooner actions.

Trigger a referral into higher-care, including telemedicine and telehealth based on a higher-risk indication from the biometric health assessment.

Meanwhile lower-risk triggers can be referred into subclinical care options for general health maintenance.



10-minute biometric health assessment



The results detect a potential elevated risk of hypertension and anxiety. All other vitals and risks reported as normal.



Risk stratifications offer recommended care pathways.

A telehealth consult is recommended to address the hypertension predicted risk.



Meanwhile for lower risk or predicted health risks that can be monitored, you can connect to health programs or subclinical options.

Population-scale health assessments and automated triage

Advanced Health Intelligence (AHI) is a leader in providing innovative health technology solutions for proactive risk management. AHI's biometric health assessments offer enhanced risk stratification and automated digital triage for scalable access and convenience at populations scale.

With AHI's smartphone-based platform, individuals can complete a comprehensive health assessment from the comfort and privacy of their own homes.

SOLUTIONS WE OFFER

- Smartphone biometric health assessments
- Population health management
- Machine-learning risk prediction for triage
- Digital biomarker underwriting

Smartphone biometrics



BodyScan

Body circumference, body composition, health indicators, health risks.

Health Risks

Obesity
T2 Diabetes [2]
Metabolic Syndrome [1]
Central Obesity

Body Composition

Total Body Fat

Circumference

Chest
Waist
Thigh
Hips

Waist-Hip
Waist-Height
BMR
FFM
LBM

Validation

Weight Prediction

Accuracy, Validation [3]

97.5%	98%
AVG ACCURACY	REPEATABILITY

1. Available by combining a Face Scan and BodyScan data, or supplying Blood Pressure.
2. Available by combining self-reported information.
3. Both accuracy and repeatability have been validated by Professor Timothy Ackland, Professor of Applied.Anatomy and Biomechanics, The University of Western Australia – ASX Announcement 18/10/2018.



FaceScan

Vital signs, cardiovascular health indicators, and health risks.

Health Risks

CVD
Heart Attack
Stroke

Vital Signs

Heart Rate
Respiratory Rate
Blood Pressure

Health Indicators

IHB
HRV
Cardiac Workload
Hypertension
Hypotension

Accuracy, Validation [1]

99%	95%	98%
HEART RATE	BLOOD PRESSURE	REPEATABILITY

1. Reference Device: Biopac Systems, ECG, 3-leads. Biopac respiration module with pneumatic belt. Biopac with continuous BP module, and Nurse using Auscultation Method. Framingham Study for risk prediction.



DermaScan™

Skin disease detection for over 500 skin conditions,.

Skin Conditions

588 Conditions
Acne
Dermatitis
Insect bites
Carcinoma
Melanoma
Shingles
...
Eczema
Psoriasis
Warts

Compliance

CE

Software as a Medical Device (Canada)

1. "Triage vs. USA Board-Certified Physicians", Company Overview September 2020

Research-led, science backed and published globally

The research and studies associated with the efficacy of our technologies has been featured in luminary publications.

Obesity Research & Clinical Practice	Agreement of anthropometric and body composition measures predicted from 2D smartphone images and body impedance scales with criterion methods
Scientific Reports	DXA reference values and anthropometric screening for visceral obesity in Western Australian adults.
Obesity Research & Clinical Practice	Obesity and visceral fat in Indonesia; An unseen epidemic? A study using iDXA and surrogate anthropometric measures.
Obesity Facts	Smartphone derived body composition and anthropometry for tracking weight loss
JDD	Artificial Intelligence in the Evaluation of Telemedicine Dermatology Patients
British Journal of Nutrition	Longitudinal concordance of body composition and anthropometric assessment by a novel smartphone application across a 12-week self-managed weight loss intervention
Journal of Community Medicine & Public Health Care	The Hidden Public Health Problem of Inadequate Sleep: Deploying Digital Mobile Technology to Improve Employee Sleep Hygiene in Asia
American Heart Association.	High Impact Employee Stress Reduction and Wellness Promotion Delivered via Digital Mobile Technology in the Construction and Aviation Industries
frontiers in Public Health	No retrenchment from employee empowerment Employer wellness imperatives and opportunities emerging from the COVID-19 pandemic.
Journal of Ecophysiology and Occupational Health	Employee Wellness in a Changing Climate: Environmental Heat Stress Driving Need for Targeted Health Promotion and Risk Reduction
Health Promotion Journal of Australia	Contextual wellness in the age of COVID-19: Managing disproportionate pandemic anxiety and stress in Australia, Singapore and other nations achieving disease control success.
IEEE Transactions on Medical Imaging	Superiority of Artificial Intelligence in the Diagnostic Performance of Malignant Melanoma Compared to Dermatologists and Primary Care Providers

Customer segments & ROI

Payor ROI – why customers buy dHaaS:

1. **Reduced cost and** risk (through early detection and intervention opportunities)
2. **Improved health and** care outcomes
3. **Process automation** (HR, health care providers)
4. **Data** – better understand customer needs, improving sales of core goods/services better



62% of smartphone users use their phone for mHealth.
A more common smartphone activity than online banking (57%), job searches (42%).

Scalable screening capabilities to support acute population screening or responses to health crises such as Monkeypox.



Source:
1. https://www.globenewswire.com/en/news-release/2022/04/11/2420173/0/en/Worldwide-3-Trillion-Health-Insurance-Market-Size-is-Expected-to-Grow-at-a-CAGR-of-over-4-4-During-2022-2028-Vantage-Market-Research.html
2. https://www.mordorintelligence.com/industry-reports/global-life-and-non-life-insurance-market--growth-trends-and-forecast-2020---2025
3. https://www.businesswire.com/news/home/20190625005862/en/The-11.9-Trillion-Global-Healthcare-Market-Key-Opportunities-Strategies-2014-2022---ResearchAndMarkets.com
4. https://stats.oecd.org/Index.aspx?DataSetCode=SHA
5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695957/

Engaged customers

AHI has the below current partners who represent a total addressable audience of over 400 million people.

AHI is working with each of these partners to complete technical integration and launch to these audiences in 2023.

Every engaged user attracts AHI license fees.

TINJOY

TRUCONNECT

BEARN
earn while you burn!

bizbaz
INTELLIGENT FINANCE

Nexus-Vita

biomorphik

The ARC
Body Vitals Meals

MVMNT

ACTIVATE

HEALTH CHECK

CHANGLIN
NETWORK TECHNOLOGY

JAYEX

PHARMAK DIRECT

IntelliGen

upvio

Our network of partners and customers represent

400 million

potential users

60 days of traction



21 June 2023

Signs Middle East Pharmacy agreement with Pharmak

https://wcsecure.weblink.com.au/clients/advancedhumanimaging/v2/headline.aspx?headlineid=61154824

5 July 2023

FDA update and research project with Stellenbosch University

https://www.newsfilecorp.com/release/172370/Advanced-Health-Intelligence-Ltd-Shareholder-Update-FDA-and-Stellenbosch-Study

2 August 2023

Signs exclusive license for China with Shanghai Changlin Network Technology

https://www.newsfilecorp.com/release/175838/Advanced-Health-Intelligence-to-reenter-China-with-Exclusive-License-Deal-with-Changlin-Network-Technology-Ltd

14 August 2023

Signs Middle East collaborative agreement with Intelligen

https://www.newsfilecorp.com/release/177072/Advanced-Health-Intelligence-Ltd-Signs-Collaboration-Agreement-with-IntelliGen-FZLLC

17 August 2023

Approved R&D rebates from Australian Government

https://www.newsfilecorp.com/release/177578/Advanced-Health-Intelligence-Obtains-Overseas-RD-Reimbursement-Under-Australias-Research-and-Development-Tax-Incentive-Scheme-RDTI

Providing equitable access to health monitoring globally

Mission

Provide health monitoring access to every smartphone user globally.

Vision

Ubiquitous health monitoring

Board and management

Nick Prosser
CHAIRMAN

- 15+ years ICT experience.
- Founder of $1.16 billion data centre exit in 2016

Scott Montgomery
CEO / DIRECTOR

- 20 years industry experience
- 2 B2B health industry exits, APAC
- Public company CEO at Australia, Canada and US public companies.

Vlado Bosanac
FOUNDER / HEAD OF STRATEGY

- 30 years capital market, investment banking and Board of Directors experience
- 4 exits (Health & Technology)
- Founder AHI

Dr Katherine Iscoe
EXECUTIVE DIRECTOR

- PhD in medical technology
- MSc Exercise Physiology & Endocrinology
- BA with Honours, Kinesiology & Exercise Science.

Jacqueline Yee
INDEPENDENT DIRECTOR

- 30years institutional investor & global capital markets structured finance experience >$25B
- Board Directorships UK and APAC
- Funderbeam Exchange CEO

Peter Goldstein
INDEPENDENT DIRECTOR

- 30 years capital market, M&A , advisory experience
- Founder of Exchange Listing, LLC. CEO of Grandview Capital Partners, Inc.

Dato Low Koon Pow
INDEPENDENT DIRECTOR

- 20 years accounting and corporate finance experience.
- Executive Director SGX company.

Mike Melby
INDEPENDENT DIRECTOR

- Founder of fintech exit to Phunware
- Investment banker and private equity investor

Terence Stupple
CTO

- 20 years IT leadership
- Government, MNC technology leadership.
- AHI CTO 7 years

Dylan Garnett
CIO

- 25 years corporate experience
- Former COO Zurich Insurance (SA), Former CEO Metropolitan Health Group

Simon Durack
CFO

- 30+ years CPA
- 20+ years Board experience

Riaan Conradie
Chief Scientist

- Brings valuable expertise across systems biology, electronics, mechanics, mathematics, physics and computer science.

Nadine Amesz
Head of Operations

- 20yrs corporate experience in contract, client and operations management.
- 4yrs EA to CE of Australia's Corruption and Crime Commission

Dr Manie de Klerk
Clinical Director

- Decades of experience in medicine, healthcare and technology incl. clinical trial expertise.
- Well-versed in technology, life sciences, and global health processes for medical approval.

Danielle du Plessis
Senior Research Scientist

- PhD in Biochemistry
- 7 years Health Industry Experience
- University of Stellenbosch

Kevin Baum
Chief Product Officer

- 35 years of experience building technology companies from start-ups to early-stage growth and public listings.

Thank-you

Scott Montgomery
Chief Executive Officer
investor@ahi.tech

Vlado Bosanac
Founder/Head of Strategy
investor@ahi.tech

For more information on how Advanced Health Intelligence how our technologies can help you, find out more at https://ahi.tech

Corporate Headquarters
Suite 5, 71-73 South Perth Esplanade,
South Perth WA 6151
hello@ahi.tech

Other locations / Asia Pacific: Perth, Melbourne, Sydney, Singapore
North America: Vancouver, Denver **South Africa:** Cape Town
Europe: Amsterdam

© 2023 Advanced Health Intelligence Ltd. All rights reserved. Apple, iPad, iPhone and App store logos are trademarks of Apple Inc. registered in the U.S. and other countries. Android and Google play are trademarks of Google LLC. All other trademarks are property of their respective owners. SPR_MTG_AHI230203

Comprehensive reporting



Summary in-app report and health score

Supplementary reports are available after completing a FaceScan and BodyScan for further biomarkers in addition to health risk predictions. A final partial summary report is available after successful completion of all 4 tiers, with an option to download/email the full report.

Comprehensive PDF report

Once complete, a PDF secure download link is emailed to the User that provides risk estimates associated with blood pressure and blood biomarkers including HbA1C, HDL, LDL, and vitals including breathing rate, body fat% and health risk predictions for obesity, 10-year Framingham cardiovascular disease and 10-year mortality risk.
The report can be taken to a medical professional for further evaluation if desired.

The report is only shared to the User, and the User can choose who and when to share it for further evaluation.

The future of healthcare is composable

Integrate seamlessly via SDK

Gartner suggests organizations that have adopted an intelligent composable approach will outpace competition by 80% in the speed of new feature implementation.

Our componentized and flexible health solutions are underpinned by an SDK integration model so you can build modular health care capabilities.

Choose the right solutions, for your desired interface and integrate with your data points to create the experience that matters for your people.

Integrate faster and enable smarter ways of working.



Source: https://www.forbes.com/sites/forbesbusinesscouncil/2022/03/02/composable-tech-why-boardrooms-should-pay-attention-and-how-to-get-started/?sh=3f0c512c6fe1

FaceScan

A health check, accessible wherever you are

FaceScan enables a quick and easy way to estimate vital signs and predict risks associated with chronic disease. Monitor health vitals and uncover comorbidity risk of cardiovascular disease, heart attack, stroke using your smartphone.

How it works

Advanced facial tracking locks onto key regions of your face using your smartphone camera.

Transdermal Optical Imaging (TOI) extracts facial blood flow information from beneath the skin.

The blood flow data is then projected into the cloud for advanced signal processing and deep learning models.

The prediction models return health vital estimations.

You receive predictions and estimates on health, indicators and risk.

Vital signs

- Heart rate
- Blood pressure
- Respiration rate

Health indicators

- Cardiac workload
- Irregular heartbeats
- Heart rate variability
- Hypertension
- Hypotension

Health risks

- Cardiovascular Disease
- Stroke
- Heart Attack
- Mental Stress Index

Accuracy, Validation [1]

99%	95%	98%	95%
HEART RATE	BLOOD PRESSURE	REPEATABILITY	PULSE PRESSURE

BodyScan

Smart body composition and dimensioning

BodyScan offers a simple way to self-assess body composition and dimension in comfort and privacy. Discover comprehensive body composition data alongside key health risk indicators associated with obesity and diabetes. Available for mobile and web.

How it works



1

Input age, biological sex, height, weight and ethnicity (once-off).

2

Place your phone in an even spot at hip-height.

3

Wear form-fitting clothing, in an uncluttered environment, with even lighting.



4

Start the scan. It can take around 30 seconds to complete.



5

Recommended to perform 3-5 scans the first time to feed more data into the algorithm.

Body circumference

- Chest
- Waist
- Hips
- Thighs

Health indicators

- Waist-hip ratio
- Waist-height ratio
- Body fat %

Health risks

- Obesity
- Type-2 Diabetes [2]
- Central obesity (Visceral Fat)
- Metabolic syndrome [3]

Accuracy, Validation [4]

97.5%	97.5%	98%	97.5%	98%
Body circumference	Weight Inference	Chest	Waist	Repeatability

DermaScan

Smart body composition and dimensioning

DermaScan provides a simple and efficient means for individuals to self-conduct a skin test in the privacy and comfort of their own home.

DermaScan uses advanced computer vision with visual classification AI trained with over 500,000 skin images to interpret and predict possible skin conditions on a smartphone, tablet or web-browser.

This technology allows for early detection and monitoring of 588 skin conditions across 134 categories including melanoma. DermaScan can also serve as a tool for medical professionals to support remote assessment for triage or as a second opinion.

The user experience features a fully guided process where users simply capture their identified area, answer a few questions about the skin condition and DermaScan then reports the 5 most likely conditions with 90% accuracy.

DermaScan is a CE device

CE

How it works



1

Input age, biological sex, height, weight and ethnicity (once-off).



2

Wear form-fitting clothing, in an uncluttered environment, with even lighting.



3

Recommended to perform 3-5 scans the first time to feed more data into the algorithm.

Conditions included:

- Basal Cell Carcinoma (The most common type of cancer worldwide – including skin cancer)
- Squamous Cell Carcinoma In Situ (The second most common skin cancer)
- Hand-Foot-and-Mouth disease
- Arthropod bites and stings
- Athlete's Foot
- Chicken Pox
- Genital Herpes and Warts
- Cold sores
- Dermatitis
- Moles
- Skin Tags
- Shingles
- Cysts
- Erythema
- Ringworm
- Tinea
- Ulcers
- Scabies
- General Warts
- Vasculitis
- Lichen Planus
- Cellulitis
- Corns and Calluses

TIER 1

Cardiovascular and mental health

FaceScan uses transdermal optical imaging to deliver health vital estimates including blood pressure, heart rate, heart rate variability and breathing rate. This is promptly followed by the GAD7 and PHQ9, the clinical standard for anxiety and depression risk detection.

Once complete the predicted risk of cardiovascular disease, hypertension, hypotension, irregular breathing rate, anxiety and depression will be displayed.

What this unlocks in the final report

Mental Health

- GAD7
- PHQ9

Blood pressure

- Systolic BP
- Diastolic BP

Cardiorespiratory health

- Resting Heart Rate
- Framingham 10-year Hard Cardiovascular Disease Risk
- Cardiorespiratory Fitness
- 10-year Cardiovascular Disease Risk

Blood Sugar

- Blood Sugar Estimation

Body measures

- Body fat %
- Waist-to-hip Ratio
- Waist Circumference
- BMI
- Waist-to-height Ratio
- Hip Circumference

Inflammation

- C-reactive Protein Estimate

Metabolic health

- Arterial stiffness estimate
- Lipid Accumulation Product Estimate
- HDL-C Estimate
- HDL-C Triglycerides Estimate
- Visceral Adiposity Index estimate
- Total Cholesterol Estimate
- LDL-C Estimate





TIER 2

Health at rest

Health at rest focusses on the cardiovascular system and predicts resting heart rate risk. Using FingerScan which features Photoplethysmography (PPG) technology, it detects volumetric changes in blood in peripheral circulation while at rest.





What this unlocks in the final report

Mental Health
- GAD7
- PHQ9

Blood pressure
- Systolic BP
- Diastolic BP

Cardiorespiratory health
- Resting Heart Rate
- Framingham 10-year Hard Cardiovascular Disease Risk
- Cardiorespiratory Fitness
- 10-year Cardiovascular Disease Risk

Blood Sugar
- Blood Sugar Estimation

Body measures
- Body fat %
- Waist-to-hip Ratio
- Waist Circumference
- BMI
- Waist-to-height Ratio
- Hip Circumference

Inflammation
- C-reactive Protein Estimate

Metabolic health
- Arterial stiffness estimate
- Lipid Accumulation Product Estimate
- HDL-C Estimate
- HDL-C Triglycerides Estimate
- Visceral Adiposity Index estimate
- Total Cholesterol Estimate
- LDL-C Estimate

TIER 3

Body dimension and composition

BodyScan is built with proprietary computer vision and machine learning processing modules, which use over 1,000's data points to generate and guide the scaled contour. This returns estimates on body dimension and composition, such as body fat %, waist hip ratio, and waist height ratio, comparable to gold standard methods.

What this unlocks in the final report

Mental Health
- GAD7
- PHQ9

Blood pressure
- Systolic BP
- Diastolic BP

Cardiorespiratory health
- Resting Heart Rate
- Framingham 10-year Hard Cardiovascular Disease Risk
- Cardiorespiratory Fitness
- 10-year Cardiovascular Disease Risk

Blood Sugar
- Blood Sugar Estimation

Body measures
- Body fat %
- Waist-to-hip Ratio
- Waist Circumference
- BMI
- Waist-to-height Ratio
- Hip Circumference

Inflammation
- C-reactive Protein Estimate

Metabolic health
- Arterial stiffness estimate
- Lipid Accumulation Product Estimate
- HDL-C Estimate
- HDL-C Triglycerides Estimate
- Visceral Adiposity Index estimate
- Total Cholesterol Estimate
- LDL-C Estimate



TIER 4

Post-exertion recovery

A 3-minute step test promptly followed by a FingerScan PPG to review cardiovascular fitness. This evenly paced stepping exercise reviews the associated risks with heart rate recovery and heart disease.



What this unlocks in the final report

Mental Health
- GAD7
- PHQ9

Blood pressure
- Systolic BP
- Diastolic BP

Cardiorespiratory health
- Resting Heart Rate
- Framingham 10-year Hard Cardiovascular Disease Risk
- Cardiorespiratory Fitness
- 10-year Cardiovascular Disease Risk

Blood Sugar
- Blood Sugar Estimation

Body measures
- Body fat %
- Waist-to-hip Ratio
- Waist Circumference
- BMI
- Waist-to-height Ratio
- Hip Circumference

Inflammation
- C-reactive Protein Estimate

Metabolic health
- Arterial stiffness estimate
- Lipid Accumulation Product Estimate
- HDL-C Estimate
- HDL-C Triglycerides Estimate
- Visceral Adiposity Index estimate
- Total Cholesterol Estimate
- LDL-C Estimate

Population-scale health reporting

Real-time health reporting for effective, scalable risk stratification for healthier populations

Customizable reporting options to provide a comprehensive and simple-to-understand summary of biomarker results and epidemiology analysis to identify key correlations or areas for focus.

Risk stratification reporting

Cohort analysis of risk across health categories and risk-rating, including the average result for your population.



Sample stress report, indexed by time of day

Engagement and activity reports

Usage and engagement analytics of the platform to identify success of implementation and roll-out.

Population heat map analysis

Risk epidemiology analytics across a population map to identify higher-risk locales for intervention opportunities..



Sample avg. resting heart rate against waist averages

Looking for something more customised?

Integrating with our API means you can get access to more data-markers and can decide how you would like the reporting to be analysed and displayed. Ask our team for more information.